ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO289

Dissection of Key Molecular Events in Podocyte Response to Hyperinsulinemia and Its Implications in Prediabetic Microalbuminuria

Session Information

Category: Diabetic Kidney Disease

  • 701 Diabetic Kidney Disease: Basic

Authors

  • Chen, Mengxuan, The University of Toledo Medical Center, Toledo, Ohio, United States
  • Ge, Yan, The University of Toledo Medical Center, Toledo, Ohio, United States
  • Dworkin, Lance D., The University of Toledo Medical Center, Toledo, Ohio, United States
  • Gong, Rujun, The University of Toledo Medical Center, Toledo, Ohio, United States
Background

Epidemiological evidence suggests that insulin resistance, manifested as compensatory hyperinsulinemia, is an independent risk factor for chronic kidney disease. However, whether hyperinsulinemia per se is a cause for kidney injury is unknown.

Methods

Pre-diabetic db/db mice were examined for renal histology, glycemia, insulinemia and albuminuria. Insulin signaling profile was estimated in glomerular podocytes in db/m and db/db mice. Immortalized podocytes were exposed to high ambient insulin, following ectopic expression of a kinase-dead mutant of GSK3β (KD), a constitutively active GSK3β mutant (S9A), or treatment with a GSK3β inhibitor tideglusib. Cell injury and insulin signaling were examined.

Results

Hyperinsulinemia preceded hyperglycemia in pre-diabetic db/db mice, and was associated with microalbuminuria and early signs of podocyte impairment. In glomeruli isolated from young db/db mice, an exhausted insulin signaling was noted, marked by insulin receptor (INSR) depletion and hypoactivity of insulin signaling mediators like IRS1 and Akt. This was associated with loss of repression of the constitutively active GSK3β, as indicated by diminished inhibitory p-GSK3βS9. GSK3β hyperactivity was also confirmed in glomerular podocytes in pre-diabetic db/db mice, correlating with the degree of hyperinsulinemia or microalbuminuria. Furthermore, GSK3β co-localized and physically interacted with IRS1 in podocytes, suggesting IRS1 acts as a putative substrate for GSK3β. In cultured podocytes, prolonged exposure to high ambient insulin depleted the expression of INSR, leading to GSK3β hyperactivity and inhibitory p-IRS1S332. S9A reinforced inhibitory p-IRS1S332 and thereby desensitized insulin signaling, as evidenced by further reduction in Akt phosphorylation. This was associated with exacerbated podocyte injury. Conversely, KD mitigated the inhibitory p-IRS1S332 and thereby restored insulin signaling sensitivity, resulting in attenuated podocyte injury. This protective effect was mimicked by tideglusib.

Conclusion

Hyperinsulinemia elicits podocyte injury and microalbuminuria via a series of key molecular events, involving depletion of INSR, desensitization of insulin signaling, and GSK3β hyperactivity, which promotes inhibitory p-IRS1S332 and thereby forms a vicious cycle of insulin signaling resistance and podocyte injury.

Funding

  • NIDDK Support